Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy.

Diagnosis and management of pituitary tumours. BMJ (1994) 1.49

Noncanonical suppression of GH-dependent isoforms of cytochrome P450 by the somatostatin analog octreotide. J Endocrinol (2013) 0.81

Growth hormone-independent suppression of growth hormone-dependent female isoforms of cytochrome P450 by the somatostatin analog octreotide. Eur J Pharmacol (2013) 0.78

Somatostatin analogue treatment of neuroendocrine tumours. Postgrad Med J (1996) 0.77

Somatostatin receptor scintigraphy in patients with pituitary adenoma. Neurosurg Rev (1997) 0.75

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch (2006) 5.86

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med (1993) 3.45

Pituitary insufficiency. Lancet (1998) 2.93

Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med (1990) 2.85

[Cushing's syndrome. I. New diagnostic developments]. Ned Tijdschr Geneeskd (2006) 2.73

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab (2008) 2.70

Octreotide. N Engl J Med (1996) 2.67

Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology (2005) 2.49

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2013) 2.27

The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev (1991) 2.20

Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med (1989) 2.13

Field study of the prevalence of lameness in horses with back problems. Vet Rec (2004) 2.11

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med (2001) 2.11

Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. Am J Med (1994) 1.93

Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res (1999) 1.92

In vivo radionuclide uptake quantification using a multi-pinhole SPECT system to predict renal function in small animals. Eur J Nucl Med Mol Imaging (2006) 1.81

Somatostatin receptors in human endocrine tumors. Cancer Res (1987) 1.77

Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet (1989) 1.76

Cortisol receptor resistance: the variability of its clinical presentation and response to treatment. J Clin Endocrinol Metab (1992) 1.72

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging (2007) 1.72

Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. J Clin Endocrinol Metab (1990) 1.71

Reference data for bone density and body composition measured with dual energy x ray absorptiometry in white children and young adults. Arch Dis Child (2002) 1.70

Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. Endocr Rev (2001) 1.69

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging (2003) 1.66

TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst (2012) 1.65

Somatostatin-receptor scintigraphy in primary breast cancer. Lancet (1994) 1.63

Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity. J Clin Endocrinol Metab (1997) 1.57

Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology (1991) 1.57

Peptide receptor imaging and therapy. J Nucl Med (2000) 1.54

Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med (1992) 1.54

[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer (2001) 1.53

Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J Med Chem (2002) 1.53

Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Radiology (1993) 1.52

[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab (2001) 1.50

Risk Factors for Hemodynamic Instability during Surgery for Pheochromocytoma. J Clin Endocrinol Metab (2009) 1.49

[Cushing's syndrome. II. New forms of treatment]. Ned Tijdschr Geneeskd (2006) 1.47

Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status. Eur J Nucl Med Mol Imaging (2015) 1.41

[From gene to disease; adrenocortical insufficiency, achalasia and disrupted tear secretion: Allgrove syndrome]. Ned Tijdschr Geneeskd (2002) 1.41

In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man. J Nucl Med (1991) 1.41

Postoperative metyrapone test in the early assessment of outcome of pituitary surgery for Cushing's disease. Clin Endocrinol (Oxf) (1997) 1.41

[Clinically non-functioning hypophyseal adenomas; diagnostic possibilities and therapeutic options]. Ned Tijdschr Geneeskd (1992) 1.40

Prognostic value of dobutamine-atropine stress technetium-99m sestamibi perfusion scintigraphy in patients with chest pain. J Am Coll Cardiol (1996) 1.40

Corticosteroid therapy in severe illness. N Engl J Med (1997) 1.38

Hepatobiliary handling of iodine-125-Tyr3-octreotide and indium-111-DTPA-D-Phe1-octreotide by isolated perfused rat liver. J Nucl Med (1993) 1.38

[Insulinoma and octreotide]. Ned Tijdschr Geneeskd (1992) 1.38

Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab (1997) 1.38

[Prolactinoma; diagnosis and treatment]. Ned Tijdschr Geneeskd (1996) 1.37

Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res (1989) 1.32

Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer (2003) 1.32

Place of radioactive iodine in treatment of thyrotoxicosis. Lancet (1986) 1.30

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med (2001) 1.30

Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer (1995) 1.28

Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab (2004) 1.28

Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2012) 1.25

Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med (2001) 1.25

Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med (1993) 1.24

Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin. Scand J Gastroenterol Suppl (1986) 1.24

Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut (1996) 1.22

The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev (1988) 1.21

[111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci (1991) 1.20

The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism. Clin Endocrinol (Oxf) (1993) 1.20

Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med (1993) 1.20

Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet (2005) 1.18

Phaeochromocytomas and sympathetic paragangliomas. Br J Surg (2009) 1.17

Laparoscopic detection and resection of insulinomas. Surgery (2000) 1.17

Endoscopic retroperitoneal adrenalectomy: lessons learned from 111 consecutive cases. Ann Surg (2000) 1.16

Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol (1999) 1.15

High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J Clin Endocrinol Metab (1986) 1.13

Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res (1998) 1.13

Thyroid hormone transport by the heterodimeric human system L amino acid transporter. Endocrinology (2001) 1.12